Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
New ACLF review article in the New England Journal of Medicine!
Three clinical experts on ACLF just published a joint review article on "Acute-on-Chronic Liver Failure". Thanks to Vicente Arroyo, Richard Moreau, and Rajiv Jalan for this excellent review and for highlighting the importance of increased clinical research and efforts to prevent decompensated cirrhosis and ACLF. The article was published today in the New England Journal of Medicine (volume 382(22): pages 2137-2145; doi: 10.1056/NEJMra1914900)More news
MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021 in Frankfurt
Management of acute-on-chronic liver failure - Course director: Prof. Jonel Trebicka - Location: Goethe University Frankfurt // Date: 01.07.2021More events